降钙素原对急性冠状动脉综合征患者行冠状动脉介入治疗后发生造影剂肾病的影响-东南大学学报医学版

降钙素原对急性冠状动脉综合征患者行冠状动脉介入治疗后发生造影剂肾病的影响

单位：东南大学附属中大医院心内科, 江苏南京 210009

分类号：R541.4;R692

出版年·卷·期（页码）：2017·36·第三期（343-347）

摘要：

目的：探讨降钙素原（PCT）对急性冠状动脉综合征（ACS）患者行经皮冠状动脉介入治疗（PCI）后发生造影剂肾病（CIN）的影响。方法：选取260例在我院心内科行PCI治疗的ACS患者，根据入院时PCT水平分为高水平（PCT>0.5 ng·ml^-1）组和低水平（PCT≤0.5 ng·ml^-1）组，探讨PCT水平对ACS患者PCI术后CIN发生率的影响及其因素。结果：260例患者共发生CIN 22例，发生率为8.5%。与低水平组（4.6%）相比，高水平组CIN发生率（12.3%）显著增加（P=0.026）。多因素Logistic回归分析显示，校正年龄、糖尿病、高脂血症、超敏C反应蛋白（hs-CRP）、估算肾小球滤过率（eGFR）、左心室射血分数（LVEF）及水化混杂因素后，PCT>0.5 ng·ml^-1是发生CIN的独立危险因素（OR=1.6，95%CI为1.2~5.31，P=0.032）。结论：高水平的PCT可能促进ACS患者PCI术后CIN的发生。

Objective:To explore the impact of procalcitonin(PCT)on contrast-induced nephropathy(CIN)after percutaneous coronary intervention(PCI)in patients with acute coronary syndrome(ACS). Methods:Two hundred and sixty patients undergoing PCI in the cardiology department of our hospital were enrolled in this study. Patients were divided into high-level group(PCT>0.5 ng·ml^-1)and low-level group(PCT ≤ 0.5 ng·ml^-1)according to PCT tertiles on admission to investigate the influence of PCT level on the incidence of CIN after PCI and its influencing factors. Results:CIN occurred in 22(8.5%)of 260 enrolled patients, and the incidence of CIN in high-level group(12.3%)was significantly increased compared with that in the low-level group(4.6%)(P=0.026). Multivariate Logistic regression analysis found that PCT>0.5 ng·ml^-1 was an independent risk factor of CIN after adjustment for age, diabetes, hyperlipidemia, hs-CRP, eGFR, LVEF and hydration confounders(OR=1.6, 95%CI 1.2-5.31, P=0.032). Conclusion:High levels of PCT may increase the occurrence of CIN after PCI in patients with ACS.

参考文献：

[1] MAEDER M,KLEIN M,FEHR T,et al.Contrast nephropathy:review focusing on prevention[J].J Am Coll Cardiol,2004,44(9):1763-1771.
[2] MCCULLOUGH P A.Contrast-induced acute kidney injury[J].J Am Coll Cardiol,2008,51(15):1419-1428.
[3] ILHAN F,AKBULUT H,KARACA I,et al.Procalcitonin,c-reactive protein and neopterin levels in patients with coronary atherosclerosis[J].Acta Cardiol,2005,60(4):361-365.
[4] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-392.
[5] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2012,40(5):353-367.
[6] STACUL F,van der MOLEN A J,REIMER P,et al.Contrast induced nephropathy:updated ESUR Contrast Media Safety Committee guidelines[J].Eur Radiol,2011,21(12):2527-2541.
[7] ARAZI H C,BADIMON J J.Anti-inflammatory effects of anti-platelet treatment in atherosclerosis[J].Curr Pharm Des,2012,18(28):4311-4325.
[8] 吴熙,于学忠.降钙素原[J].中国医学科学院学报,2008,30(2):231-235.
[9] 张声,张卫星,罗华,等.脓毒症患者血清降钙素原和C反应蛋白水平检测的临床价值[J].现代医学,2015,43(3):303-306.
[10] GEPPERT A,STEINER A,DEⅡE-KARTH G,et al.Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock[J].Intensive Care Med,2003,29(8):1384-1389.
[11] 何谊婷,谭宁,刘远辉,等.高敏C反应蛋白与经皮冠状动脉介入治疗患者对比剂肾病的相关性[J].中华心血管病杂志,2013,41(5):394-398.
[12] 周霞,金元哲,王琦,等.大剂量阿托伐他汀预防对比剂肾病[J].中华心血管病杂志,2009,37(5):394-396.
[13] MORGENTHALER N G,STRUCK J,CHANCERELLE Y,et al.Production of procalcitonin(PCT)in non-thyroidal tissue after LPS injection[J].Horm Metab Res,2003,35(5):290-295.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录